fludarabine and Infection

fludarabine has been researched along with Infection in 45 studies

Research

Studies (45)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's8 (17.78)18.2507
2000's28 (62.22)29.6817
2010's6 (13.33)24.3611
2020's3 (6.67)2.80

Authors

AuthorsStudies
Callander, N; D'Angelo, CR; Hall, A; Hematti, P; Juckett, M; Kenkre, VP; Kim, K; Longo, W; Mattison, R; Woo, KM1
Chen, A; Hayes-Lattin, B; Maziarz, RT; Murphree, C; Nagle, SJ; Nemecek, E; Raess, PW; Schachter, L1
Ayash, L; Deol, A; Kim, S; Modi, D; Ratanatharathorn, V; Singh, V; Uberti, JP1
Ali, S; Olszewski, AJ; Shafqat, H1
Butler, AC; Chan, G; Fang, L; Jewell, RC; Kipps, TJ; Laubscher, KH; Lewis, E; Lindeman, R; Patton, WN; Sedoti, D; Witman, P; Zhou, YY1
Balser, C; Barth, J; Blau, W; Boeck, HP; Brugger, W; Hahn, L; Hinke, A; Kaiser, U; Kauff, F; Losem, C; Mueller, L; Niederle, N; Rummel, M; Sandherr, M; Stauch, M; Vereshchagina, J; von Gruenhagen, U; Weidmann, E; Welslau, M1
Burgaleta, C; Cabrera, C; Canales, M; De la Serna, J; Fernández de Sevilla, A; Gonzalez, M; Martínez, R; Martínez-López, J; Montalbán, C; Monteagudo, MD; Paz-Carreira, J; Peñalver, FJ; Peñarrubia, MJ; Prieto, E; Queizán, JA; Rapado, I; Rivero, A; Salar, A; Sánchez-Godoy, P; Tomás, JF1
Cano, P; Champlin, RE; Ciurea, SO; de Lima, M; Fernandez-Vina, M; Gajewski, J; Giralt, S; Jones, RB; Kebriaei, P; Korbling, M; McMannis, J; Pesoa, S; Qazilbash, M; Qureshi, S; Rondon, G; Saliba, R; Shpall, EJ; Worth, LL1
Tam, CS1
Andritsos, L; Bechtel, T; Benson, DM; Blum, W; Byrd, JC; Devine, SM; Elder, P; Garzon, R; Hamadani, M; Hofmeister, C; Klisovic, R; Krugh, D; Lin, T; Marcucci, G; O'Donnell, L; Penza, S; Phillips, G1
Badoux, XC; Burger, J; Faderl, S; Ferrajoli, A; Kantarjian, H; Keating, MJ; Koller, C; Lerner, S; O'Brien, SM; Wang, X; Wierda, WG1
Hwang, HJ; Jeon, M; Jung, AR; Kang, YA; Kim, DY; Kim, SH; Lee, JH; Lee, KH; Lee, YS; Seol, M; Shin, HJ; Yun, SC1
Bergmann, M; Busch, R; Emmerich, B; Franke, A; Hallek, M; Hiddemann, W; Hopfinger, G; Pasold, R; Schlag, R; Schmitt, B; Wendtner, CM1
Aulitzky, WE; Diehl, V; Engert, A; Hallek, M; Hensel, M; Herold, M; Hinke, A; Huhn, D; Klein, SK; Knauf, WU; Rehwald, U; Reiser, M; Schulz, H1
Caballero, D; Chopra, R; Craddock, C; García-Conde, J; Goldstone, AH; Hunter, A; Kottaridis, PD; Leon, A; Linch, DC; Mackinnon, S; Martino, R; Milligan, DW; Parker, A; Pérez-Simón, JA; San Miguel, JF; Schey, S; Sierra, J; Sureda, A; Urbano-Ispizua, A; Yong, K1
Belohradsky, BH; Blanche, S; Bordigoni, P; Cant, A; Di Bartolomeo, P; Fischer, A; Flood, T; Gungor, T; Landais, P; Müller, S; Nagler, A; Ozsahin, H; Passwell, JH; Porta, F; Seger, RA; Slavin, S; Wulffraat, N; Zintl, F1
Arnold, R; Dörken, B; Heine, F; Le Coutre, P; Massenkeil, G; Nagy, M; Rosen, O1
Blumberg, N; Fenton, P; Horan, JT; Liesveld, JL; Walters, MC1
Beltrami, G; Carella, AM; Corsetti, MT; Musto, P; Scalzulli, P1
Bond, R; Brown, M; Campbell, P; Grigg, AP; Ritchie, D; Scarlett, J; Seymour, JF; Tam, C; Underhill, C1
Ayala, A; Cabanillas, F; Feng, L; Hagemeister, FB; McLaughlin, P; Rodriguez, MA; Romaguera, J; Smith, TL; Tsimberidou, AM; Younes, A1
Bergmann, M; Brittinger, G; Busch, R; Döhner, H; Eichhorst, BF; Emmerich, B; Hallek, M; Hensel, M; Hopfinger, G; Jäger, U; Pasold, R; Schweighofer, C; Siehl, S; Steinbrecher, C; Stilgenbauer, S; Wendtner, CM1
Forman, SJ; Kogut, N; Krishnan, A; Nademanee, A; Nakamura, R; Patane, K; Popplewell, L; Rodriguez, R; Ruel, N; Sarkodee-Adoo, C; Smith, E; Zain, J1
Daguindau, N; Feugier, P; Perrot, A; Tomowiak, C1
Catovsky, D; Dearden, CE; Dungarwalla, M; Evans, SO; Matutes, E; Riley, U1
Cortes, J; Do, KA; Kantarjian, H; Keating, MJ; Lerner, S; O'Brien, S; Tam, CS; Thomas, DA; Wen, S; Wierda, W1
Andreeff, M; Beran, M; Escudier, S; Estey, E; Kantarjian, H; Koller, C; Kornblau, S; O'Brien, S; Robertson, LE; Thall, P1
Cheson, BD1
Beran, M; Estey, E; Kantarjian, H; Keating, MJ; Kemena, A; Koller, C; Lerner, S; O'Brien, S; Plunkett, W; Robertson, L1
Bergmann, L; Fenchel, K; Hoelzer, D; Jahn, B; Mitrou, PS1
Alcala, A; Arias-Sampedro, J; Bosch, F; Fernandez, MN; Garcia-Conde, J; Guardia, R; Lopez-Lorenzo, JL; Manso, F; Martin, A; Montserrat, E; Odriozola, J; Oyarzabal, FJ; Prieto, E1
Juliusson, G1
Beran, M; Estey, E; Freireich, EJ; Kantarjian, H; Keating, MJ; Koller, C; Lerner, S; O'Brien, S; Robertson, LE1
Diehl, V; Engert, A; Hegener, K; Hübel, K; Mansmann, G; Oberhäuser, F; Schnell, R; Staib, P1
Nagler, A; Naparstek, E; Or, R; Samuel, S; Slavin, S; Varadi, G1
Bornhäuser, M; Ehninger, G; Freiberg-Richter, J; Helwig, A; Kroschinsky, F; Naumann, R; Neubauer, A; Platzbecker, U; Plettig, R; Röllig, C; Schuler, U; Thiede, C1
Antin, JH; Duffy, KM; Kathakali, A; Laport, G; Leonard, DG; Luger, SM; McDaid, K; Orloff, G; Porter, DL; Schuster, SJ; Stadtmauer, EA; Tsai, D1
Akiyama, H; Hiruma, K; Kaku, H; Karasawa, K; Kono, N; Maeda, Y; Mizuchi, D; Mori, S; Ohashi, K; Okamoto, R; Okoshi, Y; Okuyama, Y; Sakamaki, H; Sasaki, E; Sasaki, T1
Abonour, R; Kim, K; Longo, WL; Mosher, DF; Turman, NJ; Vidarsson, B; Wiersma, SR; Williams, EC; Woodson, RD1
Carella, AM; Carotenuto, M; Cascavilla, N; D'Arena, G; Greco, MM; Ladogana, S; Melillo, L; Perla, G; Sajeva, MR1
Akerstein, A; Engelhard, D; Gelfand, Y; Morecki, S; Nagler, A; Naparstek, E; Or, R; Slavin, S; Varadi, G1
Kabisch, H; Kröger, N; Krüger, W; Renges, H; Schetelig, J; Schrum, J; Siegert, W; Stute, N; Zabelina, T; Zander, AR1
Fox, RM; Grigg, AP; Seymour, JF; Szer, J1
Branson, K; Chakrabarti, S; Chakraverty, R; Chopra, R; Craddock, C; Geary, J; Goldstone, AH; Hale, G; Hunter, A; Kottaridis, PD; Linch, DC; Mackinnon, S; Mahendra, P; Milligan, DW; Parker, A; Peggs, K; Thuraisundaram, D; Verfuerth, S; Waldmann, H; Williams, CD; Yong, K1
Albitar, M; Binet, JL; Brettman, L; Byrd, J; Flinn, I; Hillmen, P; Jain, V; Keating, MJ; Rai, KR; Santabarbara, P; Wacker, B1

Reviews

5 review(s) available for fludarabine and Infection

ArticleYear
Fludarabine combination therapy for the treatment of chronic lymphocytic leukemia.
    Clinical lymphoma, 2002, Volume: 3, Issue:1

    Topics: Adolescent; Adult; Aged; Alemtuzumab; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Chlorambucil; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Forecasting; Granulocyte Colony-Stimulating Factor; Humans; Immunotherapy; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Prednisone; Randomized Controlled Trials as Topic; Remission Induction; Rituximab; Treatment Outcome; Vidarabine; Vincristine

2002
Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the European experience, 1985-2000.
    Blood, 2002, Dec-15, Volume: 100, Issue:13

    Topics: Adolescent; Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antilymphocyte Serum; Bone Marrow; Busulfan; Cause of Death; Child; Child, Preschool; Cyclophosphamide; Europe; Female; Genetic Heterogeneity; Graft vs Host Disease; Granulomatous Disease, Chronic; Hematopoietic Stem Cell Transplantation; Humans; Infection Control; Infections; Inflammation; Male; Melphalan; Neutrophils; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2002
[Chronic lymphoid leukemia and intravenous immunoglobulins].
    La Revue de medecine interne, 2007, Volume: 28 Spec No 2

    Topics: Agammaglobulinemia; Antineoplastic Agents; Cyclophosphamide; Drug Therapy, Combination; Evidence-Based Medicine; Female; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Multicenter Studies as Topic; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Remission Induction; Time Factors; Treatment Outcome; Vidarabine

2007
Infectious and immunosuppressive complications of purine analog therapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:9

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cladribine; Humans; Immune Tolerance; Infections; Pentostatin; Purines; Vidarabine

1995
Complications in the treatment of CLL with purine analogues.
    Hematology and cell therapy, 1997, Volume: 39 Suppl 1

    Topics: Anemia, Hemolytic, Autoimmune; Humans; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Neutropenia; Purine Nucleosides; Vidarabine

1997

Trials

20 trial(s) available for fludarabine and Infection

ArticleYear
Decitabine induction with myeloablative conditioning and allogeneic hematopoietic stem cell transplantation in high-risk patients with myeloid malignancies is associated with a high rate of infectious complications.
    Leukemia research, 2020, Volume: 96

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Decitabine; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infections; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Prospective Studies; Risk Factors; Survival Rate; Transplantation Conditioning; Vidarabine

2020
An open-label, single-arm, phase 1 study to assess biomarker effects, efficacy and safety of ofatumumab in patients with refractory chronic lymphocytic leukemia.
    Leukemia & lymphoma, 2015, Volume: 56, Issue:10

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arrhythmias, Cardiac; B-Lymphocytes; Biomarkers; Cardiotoxicity; Complement System Proteins; Cytokines; Drug Resistance, Neoplasm; Electrocardiography; Female; Humans; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Male; Middle Aged; Retreatment; Treatment Outcome; Vidarabine

2015
Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial.
    The Lancet. Oncology, 2016, Volume: 17, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease-Free Survival; Female; Humans; Infections; Lymphoma, Mantle-Cell; Male; Middle Aged; Recurrence; Retreatment; Rituximab; Survival Rate; Treatment Outcome; Vidarabine

2016
Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT.
    Bone marrow transplantation, 2010, Volume: 45, Issue:3

    Topics: Adolescent; Adult; Antilymphocyte Serum; Child; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Infections; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Survival Rate; T-Lymphocytes; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult

2010
Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2009, Volume: 15, Issue:11

    Topics: Adult; Aged; Animals; Anti-Infective Agents; Antilymphocyte Serum; Busulfan; Disease Susceptibility; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Immunosuppressive Agents; Infection Control; Infections; Male; Medical Audit; Methotrexate; Middle Aged; Myeloablative Agonists; Patient Isolation; Postoperative Complications; Rabbits; T-Lymphocytes; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult

2009
Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia.
    Blood, 2011, Aug-25, Volume: 118, Issue:8

    Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Chromosome Deletion; Chromosomes, Human, Pair 17; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Humans; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Rituximab; Salvage Therapy; Smith-Magenis Syndrome; Stem Cell Transplantation; Transplantation, Homologous; Vidarabine

2011
Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia.
    Blood, 2002, Nov-01, Volume: 100, Issue:9

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Cerebral Hemorrhage; Chills; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Female; Fever; Humans; Immunotherapy; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Life Tables; Male; Middle Aged; Neutropenia; Prospective Studies; Remission Induction; Rituximab; Thrombocytopenia; Treatment Outcome; Vidarabine

2002
Hematopoietic stem cell transplantation for multiply transfused patients with sickle cell disease and thalassemia after low-dose total body irradiation, fludarabine, and rabbit anti-thymocyte globulin.
    Bone marrow transplantation, 2005, Volume: 35, Issue:2

    Topics: Adolescent; Adult; Anemia, Sickle Cell; Antilymphocyte Serum; Child; Combined Modality Therapy; Female; Graft Rejection; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hemoglobinopathies; Humans; Immunosuppressive Agents; Infections; Male; Pancytopenia; Thalassemia; Transfusion Reaction; Transplantation Chimera; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2005
A reduced intensity conditioning regimen for allografting following autografting is feasible and has strong anti-myeloma activity.
    Haematologica, 2004, Volume: 89, Issue:12

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Disease-Free Survival; Feasibility Studies; Female; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Humans; Immunosuppressive Agents; Infections; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Postoperative Complications; Remission Induction; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2004
Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia.
    Blood, 2006, Feb-01, Volume: 107, Issue:3

    Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Humans; Infections; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Leukopenia; Male; Middle Aged; Remission Induction; Retrospective Studies; Thrombocytopenia; Vidarabine

2006
High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy.
    Haematologica, 2008, Volume: 93, Issue:3

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Immunotherapy; Infection Control; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Methylprednisolone; Middle Aged; Rituximab; Salvage Therapy; Vidarabine

2008
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.
    Blood, 2008, Aug-15, Volume: 112, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Follow-Up Studies; Humans; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prognosis; Recurrence; Remission Induction; Rituximab; Survival Analysis; Treatment Outcome; Vidarabine

2008
Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyt
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1994, Volume: 12, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cytarabine; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Incidence; Infections; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neutrophils; Regression Analysis; Remission Induction; Survival Analysis; Treatment Outcome; Vidarabine

1994
Phase II clinical trial of fludarabine in chronic lymphocytic leukemia on a weekly low-dose schedule.
    Leukemia & lymphoma, 1993, Volume: 10, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Drug Administration Schedule; Gastrointestinal Diseases; Humans; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Nervous System Diseases; Remission Induction; Survival Rate; Treatment Outcome; Vidarabine

1993
Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy.
    Blood, 1998, Aug-15, Volume: 92, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CD4 Lymphocyte Count; Disease Progression; Disease-Free Survival; Female; Fever; Follow-Up Studies; Hodgkin Disease; Humans; Incidence; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Life Tables; Male; Middle Aged; Neoplasms, Second Primary; Prednisolone; Remission Induction; Salvage Therapy; Survival Analysis; Treatment Outcome; Vidarabine

1998
Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2001, Volume: 7, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Chimera; Combined Modality Therapy; Cyclophosphamide; Female; Graft Survival; Graft vs Host Disease; Graft vs Tumor Effect; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infections; Male; Middle Aged; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Vidarabine

2001
Treatment of "poor risk" acute myeloid leukemia with fludarabine, cytarabine and G-CSF (flag regimen): a single center study.
    Leukemia & lymphoma, 2001, Volume: 40, Issue:3-4

    Topics: Acute Disease; Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Infections; Leukemia, Myeloid; Male; Middle Aged; Remission Induction; Salvage Therapy; Sex Factors; Vidarabine

2001
Fludarabine and mitoxantrone: effective and well-tolerated salvage therapy in relapsed indolent lymphoproliferative disorders.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Hematopoietic Stem Cell Mobilization; Humans; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neutropenia; Risk Factors; Survival Analysis; Treatment Outcome; Vidarabine

2001
Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen.
    Blood, 2002, Feb-01, Volume: 99, Issue:3

    Topics: Adolescent; Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Infections; Male; Melphalan; Middle Aged; Survival Analysis; Tissue Donors; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2002
Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.
    Blood, 2002, May-15, Volume: 99, Issue:10

    Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Demography; Humans; Immunocompromised Host; Infections; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Salvage Therapy; Survival Rate; Thrombocytopenia; Treatment Failure; Treatment Outcome; Vidarabine

2002

Other Studies

20 other study(ies) available for fludarabine and Infection

ArticleYear
Prolonged hematologic toxicity following treatment with chimeric antigen receptor T cells in patients with hematologic malignancies.
    American journal of hematology, 2021, 04-01, Volume: 96, Issue:4

    Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Bone Marrow; Combined Modality Therapy; Cyclophosphamide; Female; Ferritins; Humans; Immunotherapy, Adoptive; Infections; Kaplan-Meier Estimate; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neutropenia; Retrospective Studies; Thrombocytopenia; Vidarabine; Young Adult

2021
Comparison of myeloablative and reduced intensity conditioning unrelated donor allogeneic peripheral blood stem cell transplant outcomes for AML using thymoglobulin for GVHD prophylaxis.
    Annals of hematology, 2021, Volume: 100, Issue:4

    Topics: Aged; Allografts; Antilymphocyte Serum; Busulfan; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Infections; Leukemia, Myeloid, Acute; Lymphocyte Depletion; Male; Middle Aged; Mycophenolic Acid; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Progression-Free Survival; Retrospective Studies; T-Lymphocytes; Tacrolimus; Transplantation Conditioning; Treatment Outcome; Unrelated Donors; Vidarabine; Whole-Body Irradiation

2021
Disparate survival outcomes after front-line chemoimmunotherapy in older patients with follicular, nodal marginal zone and small lymphocytic lymphoma.
    Leukemia & lymphoma, 2015, Volume: 56, Issue:4

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Febrile Neutropenia; Female; Humans; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Male; Outcome Assessment, Health Care; Prednisone; Rituximab; SEER Program; Survival Analysis; United States; Vidarabine; Vincristine

2015
Influence of MBL-2 mutations in the infection risk of patients with follicular lymphoma treated with rituximab, fludarabine, and cyclophosphamide.
    Leukemia & lymphoma, 2009, Volume: 50, Issue:8

    Topics: Adult; Aged; Alleles; Anti-Infective Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Cyclophosphamide; Early Termination of Clinical Trials; Female; Gene Frequency; Genetic Predisposition to Disease; Genetic Variation; Haplotypes; Humans; Infections; Lymphoma, Follicular; Lymphopenia; Male; Mannose-Binding Lectin; Middle Aged; Multicenter Studies as Topic; Neutropenia; Prospective Studies; Risk; Rituximab; Spain; Vidarabine; Young Adult

2009
Charting the path to the cure of chronic lymphocytic leukemia: consolidation strategies currently lead the way.
    Leukemia & lymphoma, 2009, Volume: 50, Issue:10

    Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Combined Modality Therapy; Cyclophosphamide; Drug Resistance, Neoplasm; Feasibility Studies; Humans; Immunotherapy; Infections; Infusions, Intravenous; Injections, Subcutaneous; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Vidarabine

2009
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
    Blood, 2011, Sep-01, Volume: 118, Issue:9

    Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Female; Graft Survival; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Histocompatibility; HLA Antigens; Humans; Infections; Kaplan-Meier Estimate; Leukemia; Male; Middle Aged; Myelodysplastic Syndromes; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; T-Lymphocytes; Tissue Donors; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult

2011
Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders.
    Blood, 2002, Nov-01, Volume: 100, Issue:9

    Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Disease-Free Survival; Female; Graft vs Host Disease; Graft vs Tumor Effect; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Incidence; Infections; Life Tables; Lymphoproliferative Disorders; Male; Melphalan; Methotrexate; Middle Aged; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Spain; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; United Kingdom; Vidarabine

2002
Nonmyeloablative stem cell transplantation in patients with ALL and AML results in low nonrelapse mortality despite high rate of infections and GVHD.
    The hematology journal : the official journal of the European Haematology Association, 2004, Volume: 5, Issue:5

    Topics: Acute Disease; Adult; Antilymphocyte Serum; Busulfan; Contraindications; Cyclosporine; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Humans; Immunosuppressive Agents; Infection Control; Infections; Leukemia, Myeloid; Male; Middle Aged; Mycophenolic Acid; Mycoses; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Risk; Survival Rate; T-Lymphocytes; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2004
Early and late infectious consequences of adding rituximab to fludarabine and cyclophosphamide in patients with indolent lymphoid malignancies.
    Haematologica, 2005, Volume: 90, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cyclophosphamide; Disease Susceptibility; Female; Herpesviridae Infections; Humans; Immunocompromised Host; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Pneumonia, Pneumocystis; Risk; Rituximab; Vidarabine

2005
Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen.
    Cancer, 2005, Jul-15, Volume: 104, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CD4 Lymphocyte Count; CD4-CD8 Ratio; Dexamethasone; Female; Humans; Immunosuppression Therapy; Infections; Interferons; Lymphoma; Male; Middle Aged; Mitoxantrone; Neutropenia; Vidarabine

2005
Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2006, Volume: 12, Issue:12

    Topics: Adolescent; Adult; Aged; Busulfan; Cause of Death; Cohort Studies; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Graft vs Host Disease; Hepatic Veno-Occlusive Disease; Humans; Infections; Kaplan-Meier Estimate; Lung Diseases, Interstitial; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Postoperative Complications; Proportional Hazards Models; Reoperation; Retrospective Studies; Risk Factors; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2006
Immunosuppressive effects and clinical response of fludarabine in refractory chronic lymphocytic leukemia.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1993, Volume: 4, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Immunosuppressive Agents; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prognosis; Retrospective Studies; Vidarabine

1993
Fludarabine in resistant or relapsing B-cell chronic lymphocytic leukemia: the Spanish Group experience.
    Leukemia & lymphoma, 1996, Volume: 21, Issue:5-6

    Topics: Anemia, Hemolytic, Autoimmune; Antimetabolites, Antineoplastic; Cause of Death; Drug Evaluation; Fever; Graft vs Host Disease; Hematologic Diseases; Humans; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Life Tables; Remission Induction; Retrospective Studies; Salvage Therapy; Spain; Survival Analysis; Transfusion Reaction; Treatment Outcome; Vidarabine

1996
Suppressed neutrophil function as a risk factor for severe infection after cytotoxic chemotherapy in patients with acute nonlymphocytic leukemia.
    Annals of hematology, 1999, Volume: 78, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Fever; Humans; Idarubicin; Immunocompromised Host; Infections; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Mitoxantrone; N-Formylmethionine Leucyl-Phenylalanine; Neutropenia; Neutrophils; Phagocytosis; Respiratory Burst; Retrospective Studies; Risk Factors; Thioguanine; Vidarabine

1999
Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma.
    Bone marrow transplantation, 2000, Volume: 25, Issue:10

    Topics: Adolescent; Adult; Antilymphocyte Serum; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Disease-Free Survival; Female; Graft Survival; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infections; Life Tables; Lymphoma; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2000
Dose-reduced conditioning for allogeneic blood stem cell transplantation: durable engraftment without antithymocyte globulin.
    Bone marrow transplantation, 2000, Volume: 26, Issue:2

    Topics: Adult; Aged; Antilymphocyte Serum; Antineoplastic Agents; Busulfan; Disease-Free Survival; Female; Graft Survival; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infections; Male; Middle Aged; Neoplasms; Nuclear Family; Prospective Studies; Recurrence; Survival Rate; T-Lymphocytes; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2000
Second allogeneic peripheral blood stem cell transplantation with fludarabine-based low-intensity conditioning regimen for relapsed myelodysplastic syndrome after allogeneic bone marrow transplantation.
    International journal of hematology, 2001, Volume: 73, Issue:1

    Topics: Antineoplastic Agents; Bone Marrow Transplantation; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Infections; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2001
Fludarabine and cytarabine as a sequential infusion regimen for treatment of adults with recurrent, refractory or poor prognosis acute leukemia.
    Leukemia & lymphoma, 2001, Volume: 41, Issue:3-4

    Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Cytogenetic Analysis; Disease-Free Survival; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Infections; Infusion Pumps; Leukemia; Lung Diseases; Male; Middle Aged; Nervous System Diseases; Prognosis; Recurrence; Retrospective Studies; Survival Rate; Treatment Outcome; Vidarabine

2001
Immune reconstitution following allogeneic stem cell transplantation in recipients conditioned by low intensity vs myeloablative regimen.
    Bone marrow transplantation, 2001, Volume: 28, Issue:3

    Topics: Adolescent; Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Case-Control Studies; Cell Culture Techniques; Child; Child, Preschool; Cytotoxicity, Immunologic; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immune System; Infections; Killer Cells, Lymphokine-Activated; Lymphocyte Activation; Male; Middle Aged; Phytohemagglutinins; T-Lymphocyte Subsets; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2001
A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
    Bone marrow transplantation, 2001, Volume: 28, Issue:7

    Topics: Adult; Anemia, Refractory, with Excess of Blasts; Antilymphocyte Serum; Bone Marrow; Busulfan; Cell Count; Chromosomes, Human, Pair 7; Cyclophosphamide; Disease-Free Survival; Feasibility Studies; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Histocompatibility; Humans; Infections; Karyotyping; Methotrexate; Middle Aged; Monosomy; Myelodysplastic Syndromes; Recurrence; Survival Rate; T-Lymphocytes; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2001